Andrew Hendifar, MD, MPH

Articles by Andrew Hendifar, MD, MPH

Patient Education, Trial Design, Post-Market Surveillance, and Adoption Barriers

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 20th 2026

Dr. Soares frames patient education conversations around reassurance and clarity.

Clinical Implementation: RLE Supply Chain, Institutional Readiness, and Access

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 20th 2026

Dr. Soares identifies the most clinically important benefit of having multiple RLE options: immediate availability for patients who are clinically ready for radioligand therapy but face delays due to drug supply or shipping constraints.

Education Strategies and Evidence Interpretation Surrounding RLE Terminology

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 13th 2026

Dr. El-Haddad recommends a 2-level approach to promoting RLE terminology adoption.

RLE Terminology in Clinical Practice and Tumor Boards

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 13th 2026

Dr. Hendifar describes how RLE terminology will evolve in tumor board discussions.

Introducing Radioligand Equivalent Terminology

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 6th 2026

Dr. Hendifar explains the rationale for proposing the term radioligand equivalent (RLE).

Advantages of the 505(b)(2) Pathway and Bridging Evidence Requirements

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

July 6th 2026

Dr. Hendifar explains the specific advantages the 505(b)(2) pathway offers for radiopharmaceutical development.

Multidisciplinary Communication and FDA Approval Pathway Fundamentals

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

Published: June 30th 2026 | Updated: June 30th 2026

Dr. Soares addresses how understanding regulatory pathways benefits the multidisciplinary teams managing patients with NETs. A shared understanding of pathway terminology, particularly what a 505(b)(2) product represents, creates a common language among nuclear medicine physicians, medical oncologists, pharmacists, and radiation oncologists. This clarity reduces confusion about whether a therapy is truly novel, generic, or something in between, and directly improves the efficiency of tumor board discussions, formulary committee reviews, and patient counseling. Without this shared vocabulary, discussions stall on terminology rather than advancing to the clinically important questions of patient selection, access, and operational implementation.

Evolution of Radioligand Therapy in NETs

ByAman Chauhan, MD,Andrew Hendifar, MD, MPH,Heloisa P. Soares, MD, UNM Comprehensive Cancer Center,Ghassan El-Haddad, MD

Published: June 30th 2026 | Updated: June 30th 2026

Dr. Aman Chauhan introduces the program on radioligand equivalents and the 505(b)(2) pathway in neuroendocrine tumor (NET) treatment, joined by Dr. Andrew Hendifar, Dr. Heloisa Soares (medical director of the theranostics program at University of Utah), and Dr. Ghassan El-Haddad (vice chair for radiopharmaceutical and nuclear oncology at Moffitt Cancer Center, nuclear medicine physician and interventional radiologist).

Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic Cancer

ByAndrew Hendifar, MD, MPH

July 1st 2015

Andrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).